Aarti Drugs

{
  "main_header": {
    "sid": 657348,
    "name": "Aarti Drugs",
    "stock_name": "Aarti Drugs",
    "full_name": "Aarti Drugs Ltd",
    "name_url": "stocks-analysis/aarti-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "372.40",
    "chg": -2.45,
    "chgp": "-0.65%",
    "dir": -1,
    "prev_price": "374.85",
    "mcapval": "3,424.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524348,
    "symbol": "AARTIDRUGS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE767A01016",
    "curr_date": "Jun 24, 03:30 PM",
    "curr_time": "04:10 AM",
    "last_traded_at": "Jun 24, 03:30 PM IST",
    "bse_nse_vol": "1.71 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 24, 2026",
    "traded_date_str": "2026 06 24",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aarti-drugs-657348-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Aarti Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-is-rated-sell-by-marketsmojo-4070224",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AartiDrugsLtd_mojoScore_4070224.png",
        "date": "2026-06-24 10:10:45",
        "description": "Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 24 June 2026, providing investors with the latest insights into the stock’s performance and outlook."
      },
      {
        "title": "Aarti Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-is-rated-sell-by-marketsmojo-4050926",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AartiDrugsLtd_mojoScore_4050926.png",
        "date": "2026-06-13 10:10:36",
        "description": "Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Aarti Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-is-rated-sell-by-marketsmojo-4030454",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AartiDrugsLtd_mojoScore_4030454.png",
        "date": "2026-06-02 10:10:51",
        "description": "Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 June 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Aarti Drugs Gains 5.89%: 2 Key Factors Driving This Week’s Mixed Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-gains-589-2-key-factors-driving-this-weeks-mixed-momentum-4008622",
        "imagepath": "",
        "date": "2026-05-23 16:07:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>18 May:</strong> Stock opens at Rs.365.20, down 0.72% amid broader market weakness</p>\n                    <p><strong>19 May:</strong> Valuation upgrade signals renewed price attractiveness; stock surges 3.63% to Rs.378.45</p>\n                    <p><strong>21 May:</strong> Downgrade to Sell announced; stock dips slightly by 0.14% to Rs.380.95</p>\n                    <p><strong>22 May:</strong> Stock rebounds 2.24% to close at Rs.389.50, ending the week on a positive note</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.365.20</div></div>\n                ..."
      },
      {
        "title": "Aarti Drugs Ltd Downgraded to Sell Amid Mixed Financial and Valuation Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-valuation-signals-4004487",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AartiDrugsLtd_mojoScore_4004487.png",
        "date": "2026-05-22 08:13:57",
        "description": "Aarti Drugs Ltd has seen its investment rating downgraded from Hold to Sell as of 21 May 2026, reflecting a nuanced reassessment across quality, valuation, financial trend, and technical parameters. Despite recent positive quarterly financial results, concerns over long-term growth and relative underperformance against benchmarks have weighed heavily on the outlook for this small-cap pharmaceutical player."
      },
      {
        "title": "Aarti Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3997764",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AartiDrugsLtd_valuationdot_3997764.png",
        "date": "2026-05-19 08:01:13",
        "description": "Aarti Drugs Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, reflecting a more compelling price proposition for investors within the Pharmaceuticals & Biotechnology sector. Despite recent market headwinds and a modest decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more favourable entry point relative to historical averages and peer benchmarks."
      },
      {
        "title": "Are Aarti Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-aarti-drugs-ltd-latest-results-good-or-bad-3994978",
        "imagepath": "",
        "date": "2026-05-16 19:21:25",
        "description": "Aarti Drugs Ltd's latest financial results for Q4 FY26 present a complex picture of operational performance. The company achieved its highest-ever quarterly revenue of ₹720.30 crores, reflecting a quarter-on-quarter growth of 19.71%, which indicates strong demand recovery and improved order execution. However, this revenue growth contrasts with a year-on-year decline in net profit, which stood at ₹55.19 crores, down 12.20% from the previous year, highlighting ongoing profitability challenges.\n\nThe operating margin for the quarter was reported at 13.30%, which shows a significant sequential improvement of 420 basis points from the prior quarter. Despite this improvement, it remains below the operating margin of 13.79% achieved in the same quarter last year, indicating persistent margin pressures that the company is facing.\n\nThe financial data also reveals that while Aarti Drugs has managed to recover some op..."
      },
      {
        "title": "Aarti Drugs Q4 FY26: Strong Quarter Masks Underlying Profitability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/aarti-drugs-q4-fy26-strong-quarter-masks-underlying-profitability-concerns-3994715",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AartiDrugs_quaterlyResult_3994715.png",
        "date": "2026-05-16 14:47:21",
        "description": "Aarti Drugs Ltd., a prominent manufacturer of active pharmaceutical ingredients (APIs), pharma intermediates, and speciality chemicals, reported a mixed performance for Q4 FY26 (January-March 2026), with net profit declining 12.20% year-on-year to ₹55.19 crores despite a strong sequential recovery. The ₹3,319 crore market cap company witnessed its stock trading at ₹367.85 on May 15, 2026, down 20.07% over the past year, significantly underperforming both the benchmark indices and its sector peers."
      },
      {
        "title": "Aarti Drugs Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-is-rated-hold-by-marketsmojo-3994096",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AartiDrugsLtd_mojoScore_3994096.png",
        "date": "2026-05-16 10:10:03",
        "description": "Aarti Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 May 2026. While the rating was revised on this date, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 693,
    "sid": "657348",
    "stock_news_url": "https://www.marketsmojo.com/news/aarti-drugs-657348"
  },
  "announcements": [
    {
      "caption": "Transfer Of Equity Shares Of The Company To IEPF",
      "datetime": "16-Jun-2026",
      "details": "Newspaper Publication",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "16-Jun-2026",
      "details": "Intimation of Analyst/ Institutional Meeting",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "05-Jun-2026",
      "details": "Intimation of Analyst/Institutional Investor meet",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has declared <strong>20%</strong> dividend, ex-date: 09 Feb 26",
          "dt": "2026-02-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 30 Sep 20",
          "dt": "2020-09-30",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Aarti Drugs Ltd is Rated Sell by MarketsMOJO

2026-06-24 10:10:45

Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 24 June 2026, providing investors with the latest insights into the stock’s performance and outlook.

Read full news article

Aarti Drugs Ltd is Rated Sell by MarketsMOJO

2026-06-13 10:10:36

Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Aarti Drugs Ltd is Rated Sell by MarketsMOJO

2026-06-02 10:10:51

Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Aarti Drugs Gains 5.89%: 2 Key Factors Driving This Week’s Mixed Momentum

2026-05-23 16:07:49

Key Events This Week

18 May: Stock opens at Rs.365.20, down 0.72% amid broader market weakness

19 May: Valuation upgrade signals renewed price attractiveness; stock surges 3.63% to Rs.378.45

21 May: Downgrade to Sell announced; stock dips slightly by 0.14% to Rs.380.95

22 May: Stock rebounds 2.24% to close at Rs.389.50, ending the week on a positive note

Week Open

Rs.365.20

...

Read full news article

Aarti Drugs Ltd Downgraded to Sell Amid Mixed Financial and Valuation Signals

2026-05-22 08:13:57

Aarti Drugs Ltd has seen its investment rating downgraded from Hold to Sell as of 21 May 2026, reflecting a nuanced reassessment across quality, valuation, financial trend, and technical parameters. Despite recent positive quarterly financial results, concerns over long-term growth and relative underperformance against benchmarks have weighed heavily on the outlook for this small-cap pharmaceutical player.

Read full news article

Aarti Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-05-19 08:01:13

Aarti Drugs Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, reflecting a more compelling price proposition for investors within the Pharmaceuticals & Biotechnology sector. Despite recent market headwinds and a modest decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more favourable entry point relative to historical averages and peer benchmarks.

Read full news article

Are Aarti Drugs Ltd latest results good or bad?

2026-05-16 19:21:25

Aarti Drugs Ltd's latest financial results for Q4 FY26 present a complex picture of operational performance. The company achieved its highest-ever quarterly revenue of ₹720.30 crores, reflecting a quarter-on-quarter growth of 19.71%, which indicates strong demand recovery and improved order execution. However, this revenue growth contrasts with a year-on-year decline in net profit, which stood at ₹55.19 crores, down 12.20% from the previous year, highlighting ongoing profitability challenges. The operating margin for the quarter was reported at 13.30%, which shows a significant sequential improvement of 420 basis points from the prior quarter. Despite this improvement, it remains below the operating margin of 13.79% achieved in the same quarter last year, indicating persistent margin pressures that the company is facing. The financial data also reveals that while Aarti Drugs has managed to recover some op...

Read full news article

Aarti Drugs Q4 FY26: Strong Quarter Masks Underlying Profitability Concerns

2026-05-16 14:47:21

Aarti Drugs Ltd., a prominent manufacturer of active pharmaceutical ingredients (APIs), pharma intermediates, and speciality chemicals, reported a mixed performance for Q4 FY26 (January-March 2026), with net profit declining 12.20% year-on-year to ₹55.19 crores despite a strong sequential recovery. The ₹3,319 crore market cap company witnessed its stock trading at ₹367.85 on May 15, 2026, down 20.07% over the past year, significantly underperforming both the benchmark indices and its sector peers.

Read full news article

Aarti Drugs Ltd is Rated Hold by MarketsMOJO

2026-05-16 10:10:03

Aarti Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 May 2026. While the rating was revised on this date, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

View All News